INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $239,722 | -58.6% | 12,930 | -75.3% | 0.01% | -59.1% |
| Q2 2023 | $578,836 | +124.4% | 52,336 | +179.9% | 0.02% | +100.0% |
| Q2 2022 | $258,000 | -46.0% | 18,700 | -36.3% | 0.01% | -47.6% |
| Q1 2022 | $478,000 | +95.9% | 29,361 | +197.1% | 0.02% | -50.0% |
| Q4 2020 | $244,000 | – | 9,883 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |